177 related articles for article (PubMed ID: 30686265)
21. How should we treat tophaceous gout in patients with allopurinol hypersensitivity?
Grahame R; Simmonds HA; McBride MB; Marsh FP
Adv Exp Med Biol; 1998; 431():19-23. PubMed ID: 9598024
[TBL] [Abstract][Full Text] [Related]
22. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Becker MA; MacDonald PA; Hunt B; Gunawardhana L
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
[TBL] [Abstract][Full Text] [Related]
24. What Is Allopurinol Failure and What Should We Do About It?
Stamp LK; Dalbeth N
J Rheumatol; 2024 Jun; 51(6):556-562. PubMed ID: 38490676
[TBL] [Abstract][Full Text] [Related]
25. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
[TBL] [Abstract][Full Text] [Related]
26. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
Alten R; Mischkewitz M; Nitschmann S
Internist (Berl); 2020 May; 61(5):530-532. PubMed ID: 32130437
[No Abstract] [Full Text] [Related]
27. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
[TBL] [Abstract][Full Text] [Related]
28. Hyperuricemia and gout.
Sloan RW
J Fam Pract; 1982 May; 14(5):923-6, 930-1, 934. PubMed ID: 7042900
[TBL] [Abstract][Full Text] [Related]
29. Febuxostat efficacy in allopurinol-resistant tophaceous gout.
Uh M; Reid G
J Clin Rheumatol; 2011 Jun; 17(4):204-6. PubMed ID: 21617552
[TBL] [Abstract][Full Text] [Related]
30. Fatal allopurinol-induced hypersensitivity syndrome associated with pancreatic abnormalities.
Fathallah N; Ben Salem C; Slim R; Kaabia N; Letaief A; Bouraoui K
J Clin Rheumatol; 2010 Jun; 16(4):170-1. PubMed ID: 20511977
[TBL] [Abstract][Full Text] [Related]
31. [Fatal outcome in allopurinol hypersensitivity syndrome].
Kluger E
Ugeskr Laeger; 1998 Feb; 160(8):1179-80. PubMed ID: 9492630
[TBL] [Abstract][Full Text] [Related]
32. Febuxostat (Uloric) for chronic treatment of gout.
Med Lett Drugs Ther; 2009 May; 51(1312):37-8. PubMed ID: 19448587
[TBL] [Abstract][Full Text] [Related]
33. Approach to the treatment of hyperuricemia.
Poon SH; Hall HA; Zimmermann B
Med Health R I; 2009 Nov; 92(11):359-62. PubMed ID: 19999894
[No Abstract] [Full Text] [Related]
34. Febuxostat: a new treatment for hyperuricaemia in gout.
Edwards NL
Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
[TBL] [Abstract][Full Text] [Related]
35. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M
Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033
[TBL] [Abstract][Full Text] [Related]
36. Suspected allopurinol-induced aseptic meningitis.
Greenberg LE; Nguyen T; Miller SM
Pharmacotherapy; 2001 Aug; 21(8):1007-9. PubMed ID: 11718488
[TBL] [Abstract][Full Text] [Related]
37. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
Hilmi BA; Asmahan MI; Rosman A
Med J Malaysia; 2012 Feb; 67(1):125-6. PubMed ID: 22582566
[TBL] [Abstract][Full Text] [Related]
38. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
39. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
[TBL] [Abstract][Full Text] [Related]
40. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia.
Gutiérrez-Macías A; Lizarralde-Palacios E; Martínez-Odriozola P; Miguel-De la Villa F
BMJ; 2005 Sep; 331(7517):623-4. PubMed ID: 16166134
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
